11th July 2018

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Company's wholly owned subsidiary Cipla Medpro South Africa (Pty) Limited has signed an agreement to acquire 100% stake in Mirren (Pty) Limited, South Africa on 11th July 2018.

A detailed Press Release and disclosure as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure – I.

Thank you,

For Cipla Limited

Rajendra Chopra
Company Secretary

Encl:

1. Details as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Prepared by – Kamlesh Kulkarni

Cipla

Annexure - I

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.;	Mirren (Pty) Limited, South Africa ["Mirren"] It has turnover of R 152.1 million for the financial year ended on 28th February 2018.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	Acquisition doesn't fall within the purview of related party transactions.
c)	Industry to which the entity being acquired belongs;	Pharmaceutical business
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Acquisition of the business of Mirren to strengthen market position and to accelerate growth within OTC space.
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	Approval by the South African Competition Commission
f)	Indicative time period for completion of the acquisition;	The transaction expected to be completed before 30th September 2018
g)	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration
h)	Cost of acquisition or the price at which the shares are acquired	Cash consideration of R 450 million to be paid on closing of transaction.

i)	Percentage of shareholding / control acquired and / or number of shares acquired;	1500 issued and paid up capital of R 1.00 each representing 100% of the share capital of Mirren's share capital on a fully diluted basis.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Mirren was incorporated in 1983 in South Africa and is a manufacturer of pharmaceutical products especially in OTC space having presence in South Africa with cross border business in Namibia and Botswana. Mirren's turnover for FY18 is R 152 million; FY17: R 123 million; FY16 R 83 million.

Cipla

CIPLA SOUTH AFRICA GROWS NATIONAL FOOTPRINT WITH MIRREN ACQUISITON

11th July 2018: Cipla Medpro South Africa (Pty) Limited ("**Cipla Medpro**"), wholly owned subsidiary of Cipla Limited, India ("**Cipla**") and South Africa's fourth largest pharmaceutical company in the private sector, today announced its plans to acquire a 100% stake in Mirren (Pty) Limited ("**Mirren**"). Mirren is a South African over-the-counter (OTC) pharmaceutical manufacturer and distributor, which has been in operations for 35 years. The transaction is subject to the approval by the Competition Commission of South Africa.

Paul Miller, CEO of Cipla South Africa, said that once approved, the transaction will enhance Cipla's current OTC portfolio, by adding Mirren's well-established brands such as Broncol cough syrup, Coryx, Tensopyn, and Ultimag. This deal will also increase Cipla's local manufacturing footprint.

Lynton Lomas, director of Mirren, said: "The acquisition by Cipla will help to ensure that, the continued growth that the Mirren brands have achieved over the past three years will be sustained. The wellbeing of Mirren's dedicated staff was one of the biggest deciding factors during this process."

"We foresee that this transaction will aid Cipla greatly in future by further improving the range of quality medication that we are able to offer South Africans. Furthermore, Cipla aims to take full leverage of this proposed transaction to deliver on its ethos of "Caring for Life", by providing quality, affordable medical products", said Paul Miller.

About Cipla:

Cipla is a global pharmaceutical company which uses cutting-edge technology and innovation to meet the everyday needs of all patients. Cipla has a legacy spanning more than 80 + years as one of the most respected pharmaceutical companies in India, as well as globally. Our portfolio includes more than 1 500 products across a wide range of therapeutic categories with one quality standard globally. While delivering a long-term sustainable business, Cipla is committed to providing affordable medicines.

Cipla

Cipla was recognized globally for its pioneering role played in providing access to affordable HIV/AIDS treatment for patients at less than a dollar a day. Its world-first triple combination anti-retroviral (ARV) has helped to treat millions of patients since 2001. Cipla's research and development focuses on producing innovative products and drug delivery systems.
For more information, visit www.cipla.com

About Cipla in South Africa:

Cipla Medpro South Africa (Pty) Limited is a wholly owned subsidiary of Cipla Limited, India and fourth largest pharmaceutical company in the private sector in South Africa. Through Cipla's ethos of 'Caring for Life', Cipla Medpro produces world-class medicines at affordable prices for the public and private sectors, advancing healthcare for all South Africans.

For more information, visit www.cipla.co.za/

